Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Schizophrenia bulletin

• Publication date

  2016-03-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1093/schbul/sbv072PMID 26071208PMCID PMC4753586
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• World Medical Association Declaration of Helsinki (WMA) - Ethical principles for medical research involving human subjects

  2014cited by this paper
• Alternative pharmacologic targets for the treatment of schizophrenia: results from phase I and II trials

  2013cited by this paper
• A Randomized Exploratory Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) for Cognitive Enhancement in Schizophrenia

  2013cited by this paper
• DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS, FIFTH EDITION

  2013cited by this paper
• Alpha7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia.

  2012cited by this paper
• Food and Drug Administration commentary on methodological issues in negative symptom trials.

  2011cited by this paper
• Alpha7 neuronal nicotinic receptors as targets for novel therapies to treat multiple domains of schizophrenia.

  2011cited by this paper
• Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia.

  2011cited by this paper
• Methodological issues in negative symptom trials.

  2011cited by this paper
• Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study.

  2010cited by this paper
• Schizophrenia, "just the facts" 4. Clinical features and conceptualization.

  2009cited by this paper
• TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.

  2009cited by this paper
• The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.

  2008cited by this paper
• Healing Psychiatry: Bridging the Science/Humanism Divide.

  2008cited by this paper
• The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.

  2008cited by this paper
• Initial phase 2 trial of a nicotinic agonist in schizophrenia.

  2008cited by this paper
• Molecular targets for treating cognitive dysfunction in schizophrenia.

  2007cited by this paper
• Treating schizophrenia symptoms with an α7 nicotinic agonist, from mice to men

  2007cited by this paper
• Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

  2007cited by this paper
• Negative symptoms of schizophrenia: a problem that will not go away

  2007cited by this paper
• A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?

  2007cited by this paper
• Course of cognitive symptoms in schizophrenia: a review of the literature.

  2007cited by this paper
• Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.

  2006cited by this paper
• Proof-of-Concept Trial of an α7 Nicotinic Agonist in Schizophrenia

  2006cited by this paper
• Treatment of schizophrenia negative symptoms: future prospects.

  2006cited by this paper
• Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia.

  2004cited by this paper
• Identification of separable cognitive factors in schizophrenia.

  2004cited by this paper
• Cognitive deficits as treatment targets in schizophrenia.

  2004cited by this paper
• Prédire les pensées d'autrui : de la psychologie évolutionniste aux neurosciences cognitives

  2000cited by this paper
• World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

  2000cited by this paper
• Negative symptoms in patients with schizophrenia with special reference to the primary versus secondary distinction.

  2000cited by this paper
• Cognitive impairment in schizophrenia

  2000cited by this paper
• Neuronal Nicotinic Receptors in Dementia with Lewy Bodies and Schizophrenia

  1999cited by this paper
• Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus.

  1997cited by this paper
• Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia.

  1995cited by this paper
• Premorbid functioning, cognitive functioning, symptoms and outcome in schizophrenia.

  1993cited by this paper
• Cholinergic gating of response to auditory stimuli in rat hippocampus.

  1992cited by this paper
• Schizophrenia, just the facts. What do we know, how well do we know it?

  1988cited by this paper

• Nicotinic acetylcholine receptors-targeting drug discovery.

  2026cites this paper
• Novel drug treatments for schizophrenia.

  2026cites this paper
• A Bayesian network meta-analysis of randomized controlled trials comparing the efficacy and safety of cholinergic modulators in schizophrenia.

  2025cites this paper
• Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape

  2025cites this paper
• Knowing is Half the Battle: The Factors Leading to Efficient Recruitment of Representative Samples in Schizophrenia Research

  2025cites this paper
• The role of rodent behavioral models of schizophrenia in the ongoing search for novel antipsychotics

  2025cites this paper
• Efficacy and safety of cholinergic modulators in patients with schizophrenia: meta-analysis of randomised controlled trials.

  2025cites this paper
• Therapeutic Targeting of the α7 Nicotinic Receptor: Challenges and Prospects for Cognitive Improvement in Alzheimer's and Schizophrenia

  2025cites this paper
• Pharmacological and Mechanistic Interventions for Cognitive Impairment Associated With Schizophrenia: A Review of Registered Clinical Trials.

  2025cites this paper
• α7 nicotinic acetylcholine receptor and depression: Mechanistic insights and therapeutic prospects.

  2025cites this paper
• Acetylcholine receptor based chemogenetics engineered for neuronal inhibition and seizure control assessed in mice

  2024cites this paper
• Characterizing the binding of TC-5619 and encenicline on the alpha7 nicotinic acetylcholine receptor using PET imaging in the pig

  2024cites this paper
• Systematic Literature Review of Studies Reporting Measures of Functional Outcome or Quality of Life in People with Negative Symptoms of Schizophrenia

  2024cites this paper
• Hippocampal Availability of the α7 Nicotinic Acetylcholine Receptor in Recent-Onset Psychosis

  2024cites this paper
• Systemic Modulators: Potential Mechanism for the 5-HT System to Mediate Exercise Amelioration in Alzheimer's Disease

  2024cites this paper
• Modern synthesis of cognitive enhancers: cholinergic ligands

  2023cites this paper
• Targeting α7 nicotinic acetylcholine receptors and their protein interactions in Alzheimer's disease drug development

  2023cites this paper
• Ionotropic and metabotropic responses by alpha 7 nicotinic acetylcholine receptors.

  2023cites this paper
• Strategies for Treatment of Disease-Associated Dementia Beyond Alzheimer's Disease: An Update

  2022cites this paper
• Insights Into the Differential Desensitization of α4β2 Nicotinic Acetylcholine Receptor Isoforms Obtained With Positive Allosteric Modulation of Mutant Receptors

  2022cites this paper
• Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics

  2022cites this paper
• A narrative review of treatment interventions to improve cognitive performance in schizophrenia, with an emphasis on at-risk and early course stages.

  2022cites this paper
• Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation

  2022cites this paper
• Physiologic Functions and Therapeutic Applications of α7 Nicotinic Acetylcholine Receptor in Brain Disorders

  2022cites this paper
• A New Treatment Paradigm

  2022cites this paper
• Beyond monoamines: II. Novel applications for PET imaging in psychiatric disorders

  2022cites this paper
• Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study.

  2021cites this paper
• Cognitive Enhancers in Schizophrenia: A Systematic Review and Meta-Analysis of Alpha-7 Nicotinic Acetylcholine Receptor Agonists for Cognitive Deficits and Negative Symptoms

  2021influential citation
• Stable desensitization of α7 nicotinic acetylcholine receptors by NS6740 requires interaction with S36 in the orthosteric agonist binding site.

  2021cites this paper
• The effects of JNJ-39393406 a positive allosteric nicotine modulator on mood and cognition in patients with unipolar depression: A double-blind, add-on, placebo-controlled trial.

  2021cites this paper
• Recent Developments in Treating Cognitive Impairment Associated with Schizophrenia

  2021cites this paper
• Cognitive Deficit in Schizophrenia: From Etiology to Novel Treatments

  2021cites this paper
• Evidence for Alpha7 Nicotinic Receptor Activation During the Cough Suppressing Effects Induced by Nicotine and Identification of ATA-101 as a Potential Novel Therapy for the Treatment of Chronic Cough

  2021influential citation
• A review on emerging drug targets in treatment of schizophrenia.

  2020cites this paper
• Cholinergic Receptors and Addiction.

  2020cites this paper
• Activators of α7 nAChR as Potential Therapeutics for Cognitive Impairment.

  2020cites this paper
• LL-00066471, a novel positive allosteric modulator of α7 nicotinic acetylcholine receptor ameliorates cognitive and sensorimotor gating deficits in animal models: Discovery and preclinical characterization.

  2020cites this paper
• Cough Remedies for Children and Adolescents: Current and Future Perspectives

  2020cites this paper
• Lights and shadows of schizophrenia therapy research: Lessons from oral risperidone and olanzapine

  2020cites this paper
• Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients

  2020cites this paper
• Research advances in add-on treatment for negative symptoms and cognitive dysfunction in schizophrenia.

  2020cites this paper
• Behavioral Pharmacology of the Cholinergic System

  2020cites this paper
• Synthesis and biological evaluation of 9-fluorenone derivatives for SPECT imaging of α7-nicotinic acetylcholine receptor.

  2019cites this paper
• Discovery of novel, potent, brain-permeable and orally efficacious positive allosteric modulator of alpha 7 nicotinic acetylcholine receptor [4-(5-(4-chlorophenyl)-4-methyl-2-propionylthiophen-3-yl)benzenesulfonamide], structure activity relationship and preclinical characterization.

  2019cites this paper
• Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology

  2019cites this paper
• Radioiodinated 9-fluorenone derivatives for imaging α7-nicotinic acetylcholine receptors.

  2019cites this paper
• Dysregulation of auditory neuroplasticity in schizophrenia.

  2019cites this paper
• Alpha 7 nicotinic acetylcholine receptor and its effects on Alzheimer's disease.

  2019cites this paper
• Drug Discovery on Natural Products: From Ion Channels to nAChRs, from Nature to Libraries, from Analytics to Assays

  2019cites this paper
• Limited changes in activities of daily life performance ability among people with schizophrenia at clinical settings and the factors moderating the changes

  2019cites this paper
• Visual hallucinations, thalamocortical physiology and Lewy Body Disease: A Review.

  2019cites this paper
• Computational Dissociation of Dopaminergic and Cholinergic Effects on Action Selection and Inhibitory Control.

  2019cites this paper
• Cough: New Pharmacology.

  2019cites this paper
• Discovery and Development of Non-Dopaminergic Agents for the Treatment of Schizophrenia: Overview of the Preclinical and Early Clinical Studies.

  2019cites this paper
• Use of Cognition to Guide Decisions About the Safety and Efficacy of Drugs in Early-Phase Clinical Trials

  2019cites this paper
• Discovery of fused heterocyclic carboxamide derivatives as novel α7-nAChR agonists: Synthesis, preliminary SAR and biological evaluation.

  2019cites this paper
• Improving cognitive training for schizophrenia using neuroplasticity enhancers: Lessons from decades of basic and clinical research.

  2019cites this paper
• Computational dissociation of dopaminergic and cholinergic effects on action selection and inhibitory control

  2019cites this paper
• The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review.

  2019cites this paper
• CHRNA7 copy number gains are enriched in adolescents with major depressive and anxiety disorders.

  2018cites this paper
• Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer’s Disease, and Parkinson’s Disease

  2018cites this paper
• Cognitive Control, the Anterior Cingulate, and Nicotinic Receptors: A Case of Heterozygote Advantage

  2018cites this paper
• Ef fi cacy of different types of cognitive enhancers for patients with schizophrenia : a meta-analysis

  2018cites this paper
• Alpha7 Nicotinic Receptors as Therapeutic Targets in Schizophrenia.

  2018cites this paper
• Impaired visual, working, and verbal memory in first-episode, drug-naive patients with major depressive disorder in a Chinese population

  2018cites this paper
• Therapeutic Applications of Nicotinic Stimulation: Successes, Failures, and Future Prospects.

  2018cites this paper
• Pharmacokinetic Limitations on Effects of an Alpha7-Nicotinic Receptor Agonist in Schizophrenia: Randomized Trial with an Extended-Release Formulation

  2018cites this paper
• N-methyl-d-aspartate-type glutamate receptor modulators and related medications for the enhancement of auditory system plasticity in schizophrenia.

  2018cites this paper
• Pharmacogenetics and cognitive symptoms in schizophrenia patients treated with antipsychotics.

  2018cites this paper
• Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis

  2018cites this paper
• Designing selective modulators for the nicotinic receptor subtypes: challenges and opportunities.

  2018cites this paper
• Synthesis and radiofluorination of novel fluoren-9-one based derivatives for the imaging of α7 nicotinic acetylcholine receptor with PET.

  2018cites this paper
• α7 Nicotinic Acetylcholine Receptor: A Potential Target in Treating Cognitive Decline in Schizophrenia.

  2018cites this paper
• An Introduction to the CNS Section of Volume 7: Recent Approvals and Advances in CNS Drug Discovery

  2017cites this paper
• 3‐Furan‐2‐yl‐N‐p‐tolyl‐acrylamide, a positive allosteric modulator of the &agr;7 nicotinic receptor, reverses schizophrenia‐like cognitive and social deficits in rats

  2017cites this paper
• A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia

  2017cites this paper
• Treatment of negative symptoms: Where do we stand, and where do we go?

  2017cites this paper
• Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies

  2017cites this paper
• B‐973, a novel piperazine positive allosteric modulator of the &agr;7 nicotinic acetylcholine receptor

  2017cites this paper
• Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial

  2017cites this paper
• Therapeutic Implications of Brain–Immune Interactions: Treatment in Translation

  2017cites this paper
• Managing Negative Symptoms of Schizophrenia: How Far Have We Come?

  2017cites this paper
• Cigarette Smoking by Patients With Serious Mental Illness, 1999-2016: An Increasing Disparity.

  2017cites this paper
• Alpha‐7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta‐analysis of rodent and human studies

  2017cites this paper
• Pharmacological Augmentation of Psychosocial and Remediation Training Efforts in Schizophrenia

  2017cites this paper
• The current agonists and positive allosteric modulators of α7 nAChR for CNS indications in clinical trials

  2017cites this paper
• The α7-nACh nicotinic receptor and its role in memory and selected diseases of the central nervous system.

  2017cites this paper
• Design and synthesis of a novel series of 4-heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes as α7 nicotinic receptor agonists 2. Development of 4-heteroaryl SAR.

  2017cites this paper
• Alpha7 nAChR Agonists for Cognitive Deficit and Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Double-blind Controlled Trials

  2017influential citation
• Improving Current Treatments for Schizophrenia

  2016cites this paper
• Treating Negative Symptoms in Schizophrenia: an Update

  2016cites this paper
• Serotonergic and Cholinergic Strategies as Potential Targets for the Treatment of Schizophrenia.

  2016cites this paper
• Pharmacological Treatment of Schizophrenia::Current Issues and Future Perspectives

  2016cites this paper
• Update on New and Emerging Treatments for Schizophrenia.

  2016cites this paper
• nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.

  2016cites this paper
• Therapeutic Potential of α7 Nicotinic Acetylcholine Receptors

  2015cites this paper
• [Negative symptoms in schizophrenia: new pharmacological approaches].

  2015cites this paper
• Concentration-response relationship of the α7 nicotinic acetylcholine receptor agonist FRM-17874 across multiple in vitro and in vivo assays.

  2015cites this paper
• Neuroscience and Biobehavioral Reviews

  year unknowncites this paper